The DOI matches its Crossref record.
Induction of tumor-reactive CTL from peripheral blood and tumor-infiltrating lymphocytes of melanoma patients by in vitro stimulation with an immunodominant peptide of the human melanoma antigen MART-1.
Abstract
MART-1 is an Ag expressed on melanomas and melanocytes, and is recognized by the majority of HLA-A2-restricted tumor-specific tumor-infiltrating lymphocytes (TIL) from melanoma patients. In the present study we have analyzed 10 potential 9-mer epitopes containing the HLA-A2.1 binding motifs for their ability to induce melanoma-specific T cell lines. Antimelanoma CTL could be generated only with MART-1(27-35) peptide, which has been previously shown to be recognized by a majority of HLA-A2-restricted TIL. Anti-MART-1(35-43)-specific CTL could also be induced, but these T cells did not recognize melanoma cells. MART-1(27-35)-specific CTL could be effectively generated from a total of 11 of 12 PBL and from 3 of 3 TIL derived from HLA-A2+ melanoma patients, as well as from 2 of 4 PBL from HLA-A2+ healthy donors by in vitro stimulation with autologous PBMC pulsed with the synthetic MART-1(27-35) peptide. These CTL lines specifically lysed and release cytokines (TNF-alpha, IFN-gamma, and GM-CSF) in response to T2 cells pulsed with MART-1(27-35), as well as to HLA-A2+ MART-1+ melanoma cells. CTL generated with MART-1(27-35) also lysed uncultured HLA-A2+ melanoma cells derived from tumor biopsies, indicating that this MART-1 epitope is likely to be expressed in association with HLA-A2 on the surface of tumor cells in vivo. CTL lines generated with MART-1(27-35) mediated 25- to 100-fold higher lytic activity than MART-1-reactive CTL grown from TIL in the presence of high dose IL-2. These results demonstrate that MART-1(27-35) peptide may represent an ideal candidate for Ag-specific immunotherapy in melanoma patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Rosenberg, S. A., Yang, J. C., Schwartzentruber, D. J., Hwu, P., Marincola, F. M., Topalian, S. L., Restifo, N. P., Dudley, M. E., Schwarz, S. L., Spiess, P. J., et al. (1998) · Nature Medicine · doi:10.1038/nm0398-321 · Cited by 1,784
Self-citationImmune evasion in cancer: mechanistic basis and therapeutic strategies
Vinay, D. S., Ryan, E. P., Pawelec, G., Talib, W. H., Stagg, J., Elkord, E., Lichtor, T., Decker, W. K., Whelan, R. L., Kumara, H. M. C. S., et al. (2015) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.03.004 · Cited by 1,625
Marincola, F. M., Jaffee, E. M., Hicklin, D. J., & Ferrone, S. (1999) · Advances in Immunology · doi:10.1016/s0065-2776(08)60911-6 · Cited by 1,174
Self-citationPittet, M. J., Valmori, D., Dunbar, P. R., Speiser, D. E., Liénard, D., Lejeune, F., Fleischhauer, K., Cerundolo, V., Cerottini, J.-C., & Romero, P. (1999) · The Journal of Experimental Medicine · doi:10.1084/jem.190.5.705 · Cited by 508
Valenti, R., Huber, V., Filipazzi, P., Pilla, L., Sovena, G., Villa, A., Corbelli, A., Fais, S., Parmiani, G., & Rivoltini, L. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1819 · Cited by 493
Self-citationValmori, D., Fonteneau, J.-F., Lizana, C. M., Gervois, N., Liénard, D., Rimoldi, D., Jongeneel, V., Jotereau, F., Cerottini, J.-C., & Romero, P. (1998) · The Journal of Immunology · doi:10.4049/jimmunol.160.4.1750 · Cited by 483
Knutson, K. L., Schiffman, K., & Disis, M. L. (2001) · Journal of Clinical Investigation · doi:10.1172/jci11752 · Cited by 439
Yee, C., Savage, P. A., Lee, P. P., Davis, M. M., & Greenberg, P. D. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.162.4.2227 · Cited by 415
Clay, T. M., Custer, M. C., Sachs, J., Hwu, P., Rosenberg, S. A., & Nishimura, M. I. (1999) · The Journal of Immunology · doi:10.4049/jimmunol.163.1.507 · Cited by 410
Self-citationCancer Immunotherapy With Peptide-Based Vaccines: What Have We Achieved? Where Are We Going?
Parmiani, G., Castelli, C., Dalerba, P., Mortarini, R., Rivoltini, L., Marincola, F. M., & Anichini, A. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.11.805 · Cited by 401
Self-citationCancer vaccines based on the identification of genes encoding cancer regression antigens
Rosenberg, S. A. (1997) · Immunology Today · doi:10.1016/s0167-5699(97)84664-6 · Cited by 386
Self-citationMaeurer, M. J., Gollin, S. M., Martin, D., Swaney, W., Bryant, J., Castelli, C., Robbins, P., Parmiani, G., Storkus, W. J., & Lotze, M. T. (1996) · Journal of Clinical Investigation · doi:10.1172/jci118958 · Cited by 289
Self-citationImmunity to cancer: attack and escape in T lymphocyte–tumor cell interaction
Rivoltini, L., Carrabba, M., Huber, V., Castelli, C., Novellino, L., Dalerba, P., Mortarini, R., Arancia, G., Anichini, A., Fais, S., et al. (2002) · Immunological Reviews · doi:10.1034/j.1600-065x.2002.18809.x · Cited by 289
Self-citationJäger, E., Ringhoffer, M., Karbach, J., Arand, M., Oesch, F., & Knuth, A. (1996) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19960516)66:4<470::aid-ijc10>3.0.co;2-c · Cited by 278
Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T Lymphocytes
Wang, R.-F., Appella, E., Kawakami, Y., Kang, X., & Rosenberg, S. A. (1996) · The Journal of Experimental Medicine · doi:10.1084/jem.184.6.2207 · Cited by 272
Self-citationAbrams, S. I., Khleif, S. N., Bergmann-Leitner, E. S., Kantor, J. A., Chung, Y., Hamilton, J. M., & Schlom, J. (1997) · Cellular Immunology · doi:10.1006/cimm.1997.1224 · Cited by 91
Metadata
- Authors
- Rivoltini, L., Kawakami, Y., Sakaguchi, K., Southwood, S., Sette, A., Robbins, P. F., Marincola, F. M., Salgaller, M. L., Yannelli, J. R., Appella, E., & Rosenberg, S. A.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1995-03-01
- Volume
- 154
- Issue
- 5
- Pages
- 2257-2265
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1932934724
- Cited by
- 290
- References
- 0
- FWCI
- 13.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.